Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04817761 · ClinicalTrials.gov registry record · Phase 2
SPARK-ALL: Calaspargase Pegol in Adults With ALL
A Phase 2 study, sponsored by Institut de Recherches Internationales Servier.
- Terminated
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT04817761 is a Phase 2 study that was terminated before completion, run by Institut de Recherches Internationales Servier. The registered enrollment target is 42 participants.
The verdict
NCT04817761, a Phase 2 study, was terminated before completion, sponsored by Institut de Recherches Internationales Servier.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of this phase 2/3 study is to confirm the recommended doses and to evaluate the safety and pharmacodynamics of Calaspargase pegol for the treatment of adult patients with Philadelphia-negative Acute Lymphoblastic Leukemia.
Interventions
- DRUG Calaspargase pegol (S95015)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2021-07-07 |
| Est. Completion | 2025-03-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04817761
The ClinicalTrials.gov registry entry for NCT04817761 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institut de Recherches Internationales Servier, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Calaspargase pegol (S95015) is the first listed.
NCT04817761 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04817761 about?
NCT04817761 is a clinical study titled "SPARK-ALL: Calaspargase Pegol in Adults With ALL". The purpose of this phase 2/3 study is to confirm the recommended doses and to evaluate the safety and pharmacodynamics of Calaspargase pegol for the treatment of adult patients with Philadelphia-negative Acute Lymphoblastic Leukemia.
What is the current status of trial NCT04817761?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2021-07-07. Estimated completion is 2025-03-21.
What interventions are being tested in trial NCT04817761?
The interventions under investigation include: Calaspargase pegol (S95015) (DRUG).
Who is sponsoring clinical trial NCT04817761?
This trial is sponsored by Institut de Recherches Internationales Servier, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.